Quanterix Corp (NASDAQ:QTRX) Chairman E Kevin Hrusovsky sold 4,000 shares of the stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $16.67, for a total transaction of $66,680.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

E Kevin Hrusovsky also recently made the following trade(s):

  • On Thursday, November 1st, E Kevin Hrusovsky sold 2,829 shares of Quanterix stock. The shares were sold at an average price of $17.97, for a total transaction of $50,837.13.
  • On Tuesday, October 2nd, E Kevin Hrusovsky sold 2,995 shares of Quanterix stock. The shares were sold at an average price of $20.91, for a total transaction of $62,625.45.
  • On Wednesday, September 5th, E Kevin Hrusovsky sold 17,909 shares of Quanterix stock. The shares were sold at an average price of $14.53, for a total transaction of $260,217.77.

NASDAQ:QTRX traded up $0.11 during mid-day trading on Wednesday, reaching $16.76. 500 shares of the company’s stock were exchanged, compared to its average volume of 73,261. Quanterix Corp has a one year low of $13.00 and a one year high of $24.81. The firm has a market cap of $376.25 million and a price-to-earnings ratio of -2.02. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.76 and a current ratio of 4.11.

Quanterix (NASDAQ:QTRX) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.07). Quanterix had a negative return on equity of 52.35% and a negative net margin of 88.72%. The business had revenue of $10.59 million for the quarter, compared to the consensus estimate of $9.57 million. Sell-side analysts anticipate that Quanterix Corp will post -1.21 EPS for the current year.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Wednesday, August 22nd. Canaccord Genuity reissued a “buy” rating on shares of Quanterix in a research report on Wednesday, November 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Quanterix currently has a consensus rating of “Buy” and an average target price of $26.67.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Quanterix during the first quarter worth about $3,439,000. Northern Trust Corp acquired a new stake in Quanterix during the first quarter worth about $894,000. Bank of New York Mellon Corp acquired a new stake in Quanterix during the second quarter worth about $312,000. Acadian Asset Management LLC acquired a new stake in Quanterix during the second quarter worth about $117,000. Finally, Bellevue Group AG grew its stake in Quanterix by 97.5% during the second quarter. Bellevue Group AG now owns 165,480 shares of the company’s stock worth $2,376,000 after buying an additional 81,680 shares in the last quarter. 51.21% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/21/quanterix-corp-qtrx-chairman-e-kevin-hrusovsky-sells-4000-shares.html.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.

Read More: How to Invest in a Bull Market

Insider Buying and Selling by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.